Precision Medicine for Neurodevelopmental Disorders
STALICLA is a biotech company focused on neurodevelopmental disorders. Its unique mission is to identify, develop and bring precision medicine to patients with neurodevelopmental disorders, with a first application in autism spectrum disorder.
STALICLA’s first precision medicine STP1 aims to serve a sub-group of patients with autism spectrum disorder. STP1 is advancing towards a Phase 1b clinical trial due to start in the US second half of 2020.
STALICLA's discovery technology for precision medicine
STALICLA has developed a first-in-class neurodevelopmental disorders -focused AI technology disrupting drug discovery and development approaches in the field.